Patents Assigned to CSL Behring Gene Therapy, Inc.
  • Compositions and methods for treating beta-hemoglobinopathies
    Patent number: 11795461
    Abstract: The present disclosure provides expression vectors comprising at least two nucleic acid sequences, namely a nucleic acid sequence encoding an anti-HPRT RNAi, and a nucleic acid sequence encoding a gamma globin gene. In some embodiments, the viral vector is a self-inactivating lentiviral vector. In some embodiments, the gamma-globin gene is used to genetically correct sickle cell disease or ?-thalassemia or to reduce symptoms thereof.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: October 24, 2023
    Assignees: CSL Behring Gene Therapy, Inc., CSL Gene Therapy Pty Ltd.
    Inventors: Jeffrey Ahlers, Jeffrey Bartlett, Chi-Lin Lee, Gene-Errol Eugenio Ringpis, Geoffrey Phillip Symonds, Ming Yan
  • Bio-production of lentiviral vectors
    Patent number: 11299752
    Abstract: The present disclosure provides a method of generating a stable producer cell line. The generation of stable producer cell lines, such as those provided in accordance with the present invention, increases the reproducibility and ease of creating high titer lentiviral stocks while easing biosafety concerns and the variation in expressed envelope proteins defines the tropism of the generated virus. The present disclosure also provides for a novel lentiviral transfer vector plasmid.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: April 12, 2022
    Assignee: CSL Behring Gene Therapy, Inc.
    Inventors: Chi-Lin Lee, Jeffrey S Bartlett
  • Modulatable switch for selection of donor modified cells
    Patent number: 11213548
    Abstract: The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a GVM effect, and/or target tumor cells.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: January 4, 2022
    Assignees: CSL Behring Gene Therapy, Inc., CSL Gene Therapy Pty Ltd.
    Inventors: Christopher Walter Alma, Jeffrey Bartlett, Louis Randall Breton, Geoffrey Phillip Symonds, Ming Yan
  • Methods for discriminating between HIV-1 and lentiviral vectors
    Patent number: 11008630
    Abstract: The present disclosure provides compositions (i.e., amplification primers and probes), methods, and kits that are particularly useful for detecting and/or quantifying nucleic acids present in a sample, such as those derived from HIV or a lentiviral vector.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: May 18, 2021
    Assignees: CSL Behring Gene Therapy, Inc., CSL Gene Therapy Pty Ltd., St. Vincent's Hospital Sydney Limited, Newsouth Innovations Pty Limited
    Inventors: Anthony Dominic Kelleher, Kazuo Suzuki, Geoffrey Phillip Symonds
  • Compositions and methods for treating beta-hemoglobinopathies
    Patent number: 10961537
    Abstract: The present disclosure provides expression vectors comprising at least two nucleic acid sequences, namely a nucleic acid sequence encoding an anti-HPRT RNAi, and a nucleic acid sequence encoding a gamma globin gene. In some embodiments, the viral vector is a self-inactivating lentiviral vector. In some embodiments, the gamma-globin gene is used to genetically correct sickle cell disease or ?-thalassemia or to reduce symptoms thereof.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: March 30, 2021
    Assignees: CSL Behring Gene Therapy, Inc., CSL Gene Therapy Pty Ltd
    Inventors: Jeffrey Ahlers, Jeffrey Bartlett, Chi-Lin Lee, Gene-Errol Eugenio Ringpis, Geoffrey Phillip Symonds, Ming Yan